Regional Meetings 2017-2018

New Agents and Emerging Strategies in the Management of Early and Advanced Breast Cancer: An Interactive Grand Rounds Series

Research To Practice is pleased to offer practicing oncologists and other allied healthcare professionals throughout the United States the opportunity to attend an educational activity focused on the management of breast cancer. Each session in this regional series will include a blend of didactic minipresentations, video case presentations from clinicians in practice, interactive polling of the audience using keypad devices and follow-up discussion and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.

Please click here to learn more about our Ovarian Cancer series.

Schedule of Events:

Tuesday, January 9, 2018
12:00 PM – 1:00 PM
Education program


Faculty:
Joyce O’Shaughnessy, MD
St Louis University
St Louis, Missouri



Lunch buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Friday, January 12, 2018
7:30 AM – 8:30 AM
Education program


Faculty:
Joseph A Sparano, MD
Einstein Medical Center
Philadelphia, Pennsylvania



Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, January 31, 2018
6:30 AM – 7:30 AM
Education program


Faculty:
Ruth M O’Regan, MD
Epic Care Medical Oncology & Hematology
Pleasant Hill, California


Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Tuesday, February 6, 2018
8:00 AM – 9:00 AM
Education program


Faculty:
Joyce O’Shaughnessy, MD
Lenox Hill Hospital
New York, New York



Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Tuesday, February 6, 2018
12:00 PM – 1:00 PM
Education program


Faculty:
Mark D Pegram, MD
Beaumont Hospital Cancer Center
Royal Oak, Michigan


Lunch buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, February 8, 2018
6:00 PM
Registration and Dinner
6:30 PM – 7:30 PM
Education program


Faculty:
William J Gradishar, MD
AMITA Health
Adventist Medical Centers
Oak Brook, Illinois




Dinner buffet will be provided
For more information or to register »
Friday, February 9, 2018
12:00 PM – 1:00 PM
Education program



Faculty:
Sara A Hurvitz, MD
Van Elslander Cancer Center
Grosse Pointe Woods, Michigan


Lunch buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Monday, February 12, 2018
5:45 PM – 6:45 PM
Education program


Faculty:
Sara A Hurvitz, MD
Texas Oncology
Austin, Texas



Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, February 22, 2018
5:00 PM – 6:00 PM
Education program


Faculty:
Ruth M O’Regan, MD
Sanford Roger Maris Cancer Center
Fargo, North Dakota


Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Friday, February 23, 2018
8:00 AM – 9:00 AM
Education program


Faculty:
Harold J Burstein, MD, PhD
SUNY Downstate Medical Center
Brooklyn, New York


Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, February 28, 2018
6:00 PM – 7:00 PM
Education program


Faculty:
Ruth M O’Regan, MD
Andrews & Patel Associates
Harrisburg, Pennsylvania


Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, March 1, 2018
7:00 PM – 8:00 PM
Education program


Faculty:
William J Gradishar, MD
Delaware Society for Clinical Oncology
Newark, Delaware


Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, April 25, 2018
12:00 PM – 1:00 PM
Education program


Faculty:
Sara A Hurvitz, MD
Cancer Treatment Centers of America
Newnan, Georgia


Boxed lunch will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised, as seating is limited.

Each 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of breast cancer and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

  • Audience Polling Using Keypad Devices
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1: Pertuzumab as Adjuvant Therapy; Neratinib as Postadjuvant Therapy for HER2-Positive Disease MODULE 2: Recently Approved CDK4/6 Inhibitors in Advanced ER-Positive, HER2-Negative Disease MODULE 3: Biologic Rationale for and Available Research Data with PARP Inhibitors in Metastatic Disease MODULE 4: Checkpoint Inhibitors in Breast Cancer

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS AND PARTICIPATING FACULTY

Kimberly L Blackwell, MD
Professor of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, North Carolina

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

William J Gradishar, MD
Betsy Bramsen
Professor of Breast Oncology and
Professor of Medicine
Deputy Director, Clinical Network
Robert H Lurie
Comprehensive Cancer Center of
Northwestern University
Director, Maggie Daley Center for
Women’s Cancer Care
Interim Chief, Division of Hematology/Oncology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology/Oncology
University of California, Los Angeles
Medical Director
Jonsson Comprehensive Cancer Center
Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California
Ruth M O’Regan, MD
Professor of Medicine
Chief, Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair
in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas

Mark D Pegram, MD
Susy Yuan-Huey Hung Professor of Medicine
Director of the Breast Oncology Program
Associate Dean, Clinical Research Quality
Associate Director for Clinical Research
Stanford Cancer Institute
Stanford University School of Medicine
Stanford, California

Joseph A Sparano, MD
Professor of Medicine and Women's Health
Albert Einstein College of Medicine
Associate Chairman, Department of Oncology
Montefiore Medical Center
Bronx, New York
 

Target Audience:
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.

Learning Objectives:

  • Review emerging research data evaluating the use of approved and investigational anti-HER2 therapies to reduce the residual risk of relapse for patients with localized HER2-positive breast cancer receiving adjuvant trastuzumab/chemotherapy.
  • Develop an understanding of the mechanism of action of, available Phase III data with and current role of recently approved and investigational CDK4/6 inhibitors for the management of advanced ER-positive breast cancer.
  • Recall emerging efficacy and safety data with PARP inhibitors in patients with BRCA mutation-positive HER2-negative metastatic breast cancer, and consider the diagnostic and therapeutic implications of these findings for future clinical care.
  • Appraise the rationale for and clinical data with investigational anti-PD-1/PD-L1 antibodies for patients with metastatic breast cancer, and use this understanding to prioritize clinical trial opportunities for appropriate individuals eligible for participation.
  • Identify ongoing trials of other investigational approaches in breast cancer, and refer patients and obtain consent for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Lilly and Tesaro Inc.